Evidence map›Paper›PMID 31144053›Full record

ReviewCurrent neurology and neuroscience reports2019

Pharmacological Enhancement of Stroke Recovery.

Amit Kumar, Tomoko Kitago

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Amit KumarBurke Neurological Institute, 785 Mamaroneck Ave., White Plains, NY, 10605, USA.
Tomoko KitagoBurke Neurological Institute, 785 Mamaroneck Ave., White Plains, NY, 10605, USA. tok7002@med.cornell.edu.
Burke Medical Research Institute · USCornell University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review aims to discuss the recent literature relating to drugs for stroke recovery and to identify some of the challenges in conducting translational research for stroke recovery. RECENT

findingsAdvances in our understanding of neural repair mechanisms in pre-clinical stroke models have provided insights into potential targets for drugs that enhance the repair/recovery process. Few drugs that act on serotonergic and dopaminergic systems have been tested in humans with mixed results. The FOCUS trial, a phase III study of early administration of fluoxetine for stroke recovery, failed to replicate the promising results of the FLAME trial, but outcome measures differed between the two trials. Another drug that has recently been shown to have potential to promote motor recovery after stroke is maraviroc, an inhibitor of C-C chemokine receptor 5 that is involved in learning and memory. Various drugs, including modulators of neurotransmitters, axonal growth inhibitor blockers, and growth factors, have been examined in preclinical and clinical studies for their ability to promote neural repair, particularly in the motor system. Neuroplasticity, broadly defined as the capacity of the brain to undergo biochemical, structural, or functional changes, is heightened early after stroke when behavioral improvements are observed. Further studies are needed to determine which of these neuroplastic processes are causal to recovery and therefore appropriate targets for drugs to promote recovery. There has also been little focus on trying to distinguish processes that promote true behavioral recovery versus those that improve task success through use of compensatory strategies. Incorporation of sensitive and detailed outcome measures that assess movement quality as well as task success in both preclinical and clinical studies are needed to further elucidate appropriate drug targets and improve the translation of preclinical findings into successful clinical trials.

Indexed as

BrainHumansNeuronal PlasticityRecovery of FunctionStrokeStroke RehabilitationTranslational Research, BiomedicalNeuroplasticityNeuroprotectionPharmacotherapyStrokeStroke recovery

Identifiers

PMID31144053
OpenAlexW2946942104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.